Bioenergetic defect associated with mKATP channel opening in a mouse model carrying a mitofusin 2 mutation
暂无分享,去创建一个
J. Martinou | D. Bonneau | P. Amati‐Bonneau | P. Reynier | V. Procaccio | Romain Cartoni | A. Chevrollier | V. Guillet | N. Gueguen | V. Desquiret | Claire Angebault
[1] O. Poirot,et al. Expression of mitofusin 2(R94Q) in a transgenic mouse leads to Charcot-Marie-Tooth neuropathy type 2A. , 2010, Brain : a journal of neurology.
[2] J. Martinou,et al. Role of mitofusin 2 mutations in the physiopathology of Charcot–Marie–Tooth disease type 2A , 2009, Experimental Neurology.
[3] A. Wojtovich,et al. The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial KATP channels , 2009, Basic Research in Cardiology.
[4] L. Scorrano,et al. Mitofusin 2 tethers endoplasmic reticulum to mitochondria , 2008, Nature.
[5] J. Pollard,et al. Histopathological Findings in Hereditary Motor and Sensory Neuropathy of Axonal Type With Onset in Early Childhood Associated With Mitofusin 2 Mutations , 2008, Journal of neuropathology and experimental neurology.
[6] P. Brookes,et al. The endogenous mitochondrial complex II inhibitor malonate regulates mitochondrial ATP-sensitive potassium channels: implications for ischemic preconditioning. , 2008, Biochimica et biophysica acta.
[7] C. Blackstone,et al. Metalloprotease‐mediated OPA1 processing is modulated by the mitochondrial membrane potential , 2008, Biology of the cell.
[8] S. Dimauro,et al. Mitochondrial fusion and function in Charcot–Marie–Tooth type 2A patient fibroblasts with mitofusin 2 mutations , 2008, Experimental Neurology.
[9] T. Eggermann,et al. Mitofusin 2 gene mutation (R94Q) causing severe early‐onset axonal polyneuropathy (CMT2A) , 2007, European journal of neurology.
[10] D. Bonneau,et al. Mitochondrial coupling defect in Charcot–Marie–Tooth type 2A disease , 2007, Annals of neurology.
[11] D. Chan,et al. Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations , 2007, The Journal of cell biology.
[12] I. Mavelli,et al. Downmodulation of mitochondrial F0F1 ATP synthase by diazoxide in cardiac myoblasts: a dual effect of the drug. , 2007, American journal of physiology. Heart and circulatory physiology.
[13] A. Pestronk,et al. Altered Axonal Mitochondrial Transport in the Pathogenesis of Charcot-Marie-Tooth Disease from Mitofusin 2 Mutations , 2007, The Journal of Neuroscience.
[14] D. Chan. Mitochondrial fusion and fission in mammals. , 2006, Annual review of cell and developmental biology.
[15] J. Lupski,et al. MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. , 2006, Brain : a journal of neurology.
[16] J. Shaw,et al. Mitochondrial morphology and dynamics in yeast and multicellular eukaryotes. , 2005, Annual review of genetics.
[17] P. Bénit,et al. Succinate dehydrogenase deficiency in human , 2005, Cellular and Molecular Life Sciences CMLS.
[18] H. McBride,et al. Activated Mitofusin 2 Signals Mitochondrial Fusion, Interferes with Bax Activation, and Reduces Susceptibility to Radical Induced Depolarization*[boxs] , 2005, Journal of Biological Chemistry.
[19] M. Palacín,et al. The Charcot-Marie-Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system. , 2005, Human molecular genetics.
[20] M. Pericak-Vance,et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A , 2004, Nature Genetics.
[21] E. Marbán,et al. Multiprotein complex containing succinate dehydrogenase confers mitochondrial ATP-sensitive K+ channel activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[22] I. Mavelli,et al. Diazoxide affects the IF1 inhibitor protein binding to F1 sector of beef heart F0F1ATPsynthase. , 2004, Biochemical pharmacology.
[23] D. Busija,et al. Diazoxide induces delayed pre‐conditioning in cultured rat cortical neurons , 2003, Journal of neurochemistry.
[24] I. Hassinen,et al. Ischaemic preconditioning and a mitochondrial KATP channel opener both produce cardioprotection accompanied by F1F0-ATPase inhibition in early ischaemia , 2003, Basic Research in Cardiology.
[25] J. Zierath,et al. Mitofusin-2 Determines Mitochondrial Network Architecture and Mitochondrial Metabolism , 2003, The Journal of Biological Chemistry.
[26] D. Kopustinskiene,et al. Adenine Nucleotide Translocase Mediates the KATP-Channel-Openers-Induced Proton and Potassium Flux to the Mitochondrial Matrix , 2003, Journal of bioenergetics and biomembranes.
[27] D. Busija,et al. Opening of Mitochondrial ATP-Sensitive Potassium Channels Is a Trigger of 3-Nitropropionic Acid–Induced Tolerance to Transient Focal Cerebral Ischemia in Rats , 2003, Stroke.
[28] Erik E. Griffin,et al. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development , 2003, The Journal of cell biology.
[29] S. Javadov,et al. The effects of ischaemic preconditioning, diazoxide and 5‐hydroxydecanoate on rat heart mitochondrial volume and respiration , 2002, The Journal of physiology.
[30] J. Daut,et al. KATP channel‐independent targets of diazoxide and 5‐hydroxydecanoate in the heart , 2002, The Journal of physiology.
[31] A. Kowaltowski,et al. Identification and Properties of a Novel Intracellular (Mitochondrial) ATP-sensitive Potassium Channel in Brain* , 2001, The Journal of Biological Chemistry.
[32] W. Neupert,et al. Connection of the Mitochondrial Outer and Inner Membranes by Fzo1 Is Critical for Organellar Fusion , 2001, The Journal of cell biology.
[33] Anirban Banerjee,et al. Mitochondrial oxidative phosphorylation thermodynamic efficiencies reflect physiological organ roles. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.
[34] T. Bourgeron,et al. Biochemical and molecular investigations in respiratory chain deficiencies. , 1994, Clinica chimica acta; international journal of clinical chemistry.
[35] L. Hederstedt,et al. New properties of Bacillus subtilis succinate dehydrogenase altered at the active site. The apparent active site thiol of succinate oxidoreductases is dispensable for succinate oxidation. , 1989, The Biochemical journal.
[36] H. Skre,et al. Genetic and clinical aspects of Charcot‐Marie‐Tooth's disease , 1974, Clinical genetics.
[37] R. Porten,et al. Diazoxide, an inhibitor of succinate oxidation , 1969 .
[38] R. Portenhauser,et al. Diazoxide, an inhibitor of succinate oxidation. , 1969, Biochemical pharmacology.
[39] I. West,et al. The direct physiological effects of mitoK(ATP) opening on heart mitochondria. , 2006, American journal of physiology. Heart and circulatory physiology.
[40] H. Schägger,et al. Blue native PAGE , 2006, Nature Protocols.
[41] K. Hayasaka,et al. Mitochondrial GTPase mitofusin 2 mutation in Charcot–Marie–Tooth neuropathy type 2A , 2004, Human Genetics.